FXR is thus considered the pharmaceutical target for developing drugs for non-alcoholic steatohepatitis (NASH) and non-alcoholic fatty liver disease (NAFLD), and synthetic agonists, such as obeticholic acid, tropifexor, cilofexor, EDP-305, and MET-409 have been developed and used in clinical practice or under clinical trials [106,107,108]. The gene discussed is NR1H4; the disease is metabolic dysfunction-associated steatohepatitis.